Oncology
For years, Sara worked in a hospital, making care possible for others. Now, after being diagnosed with breast cancer, she was the one in need of care.
Explore end-to-end solutions throughout development — from portfolio optimization and regulatory strategy, to Phase I-IV clinical trials, market access planning, and more.
See solutionsWHAT WE DO
HOW WE DO IT
Utilize our expertise across therapeutic areas, combining innovative trial designs, leading clinical and regulatory expertise, global reach, and a passion for changing patient lives.
See expertiseTherapeutic Expertise
Cross-Therapeutic Expertise
Our experts help you stay at the forefront of the industry - and ahead of change.
See insightsNew Medicines, Novel Insights
Discussions on Diversity
Thinking about joining a clinical trial? Learn the drug development process, what it’s like to participate, how to find a trial, and answers to frequently asked questions.
Learn moreFor years, Sara worked in a hospital, making care possible for others. Now, after being diagnosed with breast cancer, she was the one in need of care.
It took 10 years of treatments for Anisha's IBD to enter remission. But it came back in 2019 — and just as she was about to start treatment, the pandemic hit.
Want to collaborate with us to offer clinical trials at your site? We would welcome the opportunity to discuss.
Learn moreWe are one of the largest CROs in the world, speeding life-changing medicine to market by engaging patients With Heart™. Learn about who we are, what we do, and what we believe.
About ParexelWhat can we help you find today?
The European Union Clinical Trial Regulation 536/2014 (EU-CTR) aims to standardize and harmonize the conduct and management of interventional clinical trials across the European Economic Area (EEA), with legally binding rules on requirements and increased transparency. The new EU-CTR promises a simplified process designed to decrease the burden resulting from idiosyncratic interpretations of the current EU-CTD. But to reap efficiencies, sponsors must sow operational changes. This article covers the six essential preparations companies should undertake now.
Related Insights
Blog
Adoption of the ICH Q12 guideline: New Horizons for Efficient Product Supply Chain Management for a Key Global Market
Nov 13, 2023
Blog
Ensuring future success in a new market by delivering a robust safety database solution
Aug 4, 2023
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Article
Lessons from China and the United States on the use of RWE in regulatory submissions
Jul 19, 2021
Video
Part 2: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Video
Part 3: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Blog
Biosimilar Development: Are therapeutic clinical trials needed?
Nov 16, 2021
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Article
How emerging biotechs can enter the Chinese market and prosper
Jan 18, 2022
Video
Creating EU-CTR compliant and patient-friendly lay language summaries (LLS)
Jan 26, 2022
Article
New endpoints for early-stage cancer are gaining regulatory traction
Jan 28, 2022